for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CSL Limited

CSL.AX

Latest Trade

277.71AUD

Change

0.52(+0.19%)

Volume

597,386

Today's Range

274.90

 - 

282.74

52 Week Range

173.33

 - 

287.31

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
277.19
Open
281.63
Volume
597,386
3M AVG Volume
16.40
Today's High
282.74
Today's Low
274.90
52 Week High
287.31
52 Week Low
173.33
Shares Out (MIL)
453.14
Market Cap (MIL)
125,807.80
Forward P/E
40.80
Dividend (Yield %)
0.83

Next Event

Half Year 2020 CSL Ltd Earnings Release

Latest Developments

More

CSL Ltd Sees Net Profit After Tax For FY20 Between About $2.05 Bln To $2.11 Bln

CSL Ltd Posts FY Underlying Net Profit After Tax At Constant Currency US$2.0 Bln

CSL Updates On Its FY20 Transition To Own Distributor Model In China

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CSL Limited

CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.

Industry

Biotechnology & Drugs

Contact Info

45 Poplar Road,, Parkville

+61.3.93891911

https://www.csl.com/

Executive Leadership

Brian Anthony McNamee

Non-Executive Independent Chairman of the Board

Paul Perreault

Chief Executive Officer, Managing Director, Executive Director

David Mark Lamont

Chief Financial Officer

Paul F. McKenzie

Chief Operating Officer

Elizabeth Walker

Chief Human Resource Officer, Executive Vice President

Key Stats

2.17 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

6.6K

2018

7.6K

2019

8.5K

2020(E)

9.0K
EPS (USD)

2017

2.931

2018

3.809

2019

4.226

2020(E)

4.652
Price To Earnings (TTM)
44.91
Price To Sales (TTM)
10.09
Price To Book (MRQ)
16.37
Price To Cash Flow (TTM)
37.54
Total Debt To Equity (MRQ)
88.79
LT Debt To Equity (MRQ)
80.78
Return on Investment (TTM)
20.21
Return on Equity (TTM)
16.62

Latest News

Latest News

UPDATE 2-Australia's CSL sees another record profit in 2020; shares soar

* Record FY profit at $1.92 billion, up 11% (Recasts, adds share move, analyst comment, segmental sales)

Australia shares join global rally as miners bounce, CSL gains

Australian shares joined a global equities rally on Wednesday as heavyweight mining stocks benefited after Washington delayed tariffs on some Chinese imports that were slated to take effect in September.

Australia's CSL posts record annual profit, sees even better performance next year

CSL Ltd, Australia's fourth-largest listed company, on Wednesday reported record earnings for 2019 and forecast a better profit for the next year.

Australia shares dragged by CSL losses, NZ gains

Australian shares fell on Wednesday, erasing early gains as heavyweight drugmaker CSL dragged the index after posting a disappointing first-half profit rise.

UPDATE 2-Investors impatient as Australia's CSL shows signs of slowing growth

* Company upgrades FY guidance to top of $1.88-1.95 bln range

Australia's CSL posts 10 pct increase in 1st-half profit

Australian pharmaceutical behemoth CSL Ltd said on Wednesday its first-half profit grew 10.1 percent following stronger drug sales in the United States, and raised its full-year guidance to the upper end of an earlier provided range.

Australian pharma CSL's profit surges nearly 30 percent as U.S. drug sales spike

Australian biotherapeutics company CSL Ltd <CSL.AX> reported a near 30 percent rise in annual net profit on Wednesday, thanks to strong drug sales in the United States.

Australia's CSL posts near 30 pct profit rise as U.S. drug sales spike

Australian biotherapeutics company CSL Ltd reported a near 30 percent rise in annual net profit on Wednesday, thanks to strong drug sales in the United States.

UPDATE 2-CSL becomes Australian top 5 firm as profit outlook sends shares surging

* CSL sees annual net profit seen between $1.68 bln and $1.71 bln

Australia shares hurt by materials losses, CSL shines on profit upgrade; NZ gain

Australian shares pulled back slightly on Friday as weak commodity prices hit material stocks and tempered a rally in the healthcare sector, which was buoyed by an earnings upgrade from biotherapeutics firm CSL Ltd.

Australia's CSL lifts full-year profit outlook

Biotherapeutics company CSL Ltd on Friday lifted its full-year profit guidance for a second time this year, thanks to better-than-expected product sales.

BRIEF-CSL Behring Announces First Patient Enrollment In Phase 3 Clinical Trial Of CSL112

* CSL BEHRING ANNOUNCES FIRST PATIENT ENROLLMENT IN PHASE 3 CLINICAL TRIAL OF CSL112 TO ASSESS REDUCTION OF EARLY RECURRENT CARDIOVASCULAR EVENTS IN HEART ATTACK SURVIVORS

UPDATE 1-Australia's CSL lifts outlook after H1 profit jump; stock at record high

Biotherapeutics company CSL Ltd reported a 35 percent rise in its first-half profit on Wednesday due to robust demand for its vaccines in the United States, and upgraded its earnings guidance for the fiscal year.

Australia's CSL's half-year profit jumps 35 percent on profit rise

Biotherapeutics company CSL Ltd reported a 35 percent rise in its first half profit on Wednesday and upgraded its earnings guidance for the fiscal year.

BRIEF-CSL Says HY Net Profit After Tax For Period Attributable To Members US$1.1 Bln

* HY NET PROFIT AFTER TAX FOR PERIOD ATTRIBUTABLE TO MEMBERS UP 34.9 PERCENT TO US$1.1 BILLION

BRIEF-CSL ‍Says Brian Mcnamee Will Assume Position Of Chairman-Elect​

* JOHN SHINE AC HAS ANNOUNCED HIS INTENTION TO RETIRE AS CHAIRMAN Source text for Eikon: Further company coverage:

BRIEF-CSL And HBM Portfolio Company Vitaeris Announce Strategic Partnership

* CSL AND HBM PORTFOLIO COMPANY VITAERIS ANNOUNCE STRATEGIC PARTNERSHIP WITH OPTION TO ACQUIRE Source text - http://bit.ly/2jhdF6b Further company coverage: (Gdynia Newsroom)

BRIEF-CSL closes new US$700 million private placement in U.S.

* On 4 October, closed a new US$700 million private placement in U.S. Source text for Eikon: Further company coverage:

BRIEF-CSL receives US FDA approval of privigen for CIDP indication

* Has approved CSL Behring's Privigen for treatment of adults with chronic inflammatory demyelinating polyneuropathy to improve neuromuscular disability Source text for Eikon: Further company coverage:

BRIEF-CSL's unit says ‍new phase III study shows significantly greater efficacy in children 6-24 months who receive AQIV​

* New phase III study shows significantly greater efficacy in children 6-24 months who receive adjuvanted influenza vaccine (AQIV)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up